A
AVBP
vs
S&P 500
S&P 500
Over the past 12 months, AVBP has underperformed S&P 500, delivering a return of -14% compared to the S&P 500's +12% growth.
Stocks Performance
AVBP vs S&P 500
Performance Gap
AVBP vs S&P 500
Performance By Year
AVBP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Arrivent Biopharma Inc
Glance View
Arrivent Biopharma Inc is a US-based company operating in industry. The company is headquartered in Newtown Square, Pennsylvania and currently employs 40 full-time employees. The company went IPO on 2024-01-26. ArriVent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. The company is also focused on development and commercialization of the ARR-002 program.
